Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Current Leases (2019 - 2025)

Amphastar Pharmaceuticals has reported Current Leases over the past 7 years, most recently at $7.9 million for Q4 2025.

  • Quarterly results put Current Leases at $7.9 million for Q4 2025, up 16.52% from a year ago — trailing twelve months through Dec 2025 was $7.9 million (up 16.52% YoY), and the annual figure for FY2025 was $7.9 million, up 16.52%.
  • Current Leases for Q4 2025 was $7.9 million at Amphastar Pharmaceuticals, up from $7.8 million in the prior quarter.
  • Over the last five years, Current Leases for AMPH hit a ceiling of $7.9 million in Q4 2025 and a floor of $2.9 million in Q3 2021.
  • Median Current Leases over the past 5 years was $3.7 million (2021), compared with a mean of $4.5 million.
  • Biggest five-year swings in Current Leases: decreased 21.35% in 2021 and later soared 97.17% in 2025.
  • Amphastar Pharmaceuticals' Current Leases stood at $3.0 million in 2021, then grew by 0.7% to $3.0 million in 2022, then skyrocketed by 30.07% to $3.9 million in 2023, then soared by 74.19% to $6.8 million in 2024, then grew by 16.52% to $7.9 million in 2025.
  • The last three reported values for Current Leases were $7.9 million (Q4 2025), $7.8 million (Q3 2025), and $7.9 million (Q2 2025) per Business Quant data.